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Background: Sickle cell anemia is a chronic inflammatory disease characterized by an 
increased production of proinflammatory cytokines including tumor necrosis factor-alpha. 
Hydroxyurea, by decreasing the polymerization of hemoglobin, reduces inflammatory 
states. The effect of the genetic polymorphisms of sickle cell patients on tumor necrosis 
factor-alpha levels remains unknown.
Objective: The aim of this study was to investigate the association of tumor necrosis factor-
alpha levels with β-globin haplotypes and the use of hydroxyurea.
Methods: A cross-sectional study was performed of 67 patients with sickle cell anemia 
diagnosed at steady-state in a referral hospital in Fortaleza, Ceará, Brazil. A group of 26 
healthy individuals was used as control. βS-haplotype analysis was performed by restriction 
fragment length polymorphism-polymerase chain reaction. The tumor necrosis factor-
alpha levels were measured by the enzyme-linked immunosorbent assay test. Laboratory 
data (complete blood count and fetal hemoglobin) and information regarding the use of 
hydroxyurea were obtained from medical records. Statistical analysis was performed using 
R software with the Kruskal-Wallis and Mann-Whitney tests. Statistical significance was 
established for p-values < 0.05 for all analyses.
Results: The mean age of the participants was 35.48 years. Patients with sickle cell anemia 
had significantly higher tumor necrosis factor-alpha levels than controls (p-values < 
0.0001). Tumor necrosis factor-alpha levels were lower in sickle cell anemia patients who 
were receiving hydroxyurea treatment than those who were not (p-value = 0.1249). Sickle 
cell anemia patients with Bantu/n genotype had significantly higher levels than patients 
with the Bantu/Benin genotype (p-value = 0.0021).
Conclusion: In summary, βS-globin haplotypes, but not hydroxyurea therapy, have a role in 
modulating tumor necrosis factor-alpha levels in sickle cell anemia adults at steady-state. 
Many previous studies have investigated prognosis and inflammatory states in sickle cell 
anemia patients, but the discovery that tumor necrosis factor-alpha levels vary according 
to the genetic polymorphism of the patient  is a new finding.
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Introduction
Sickle cell anemia (SCA) is a genetic disorder characterized 
by a point mutation in the beta globin gene generating, 
when homozygous, an abnormal hemoglobin known as 
hemoglobin S (Hb S).1,2 Clinical manifestations result from 
the tendency of Hb S to polymerize in the deoxygenated 
state, causing vascular obstructions and ischemia, and 
consequent painful crises associated with episodes of 
chronic hemolysis.1,3 
The vaso-occlusive crisis is the most common symptom 
in SCA patients, manifesting in 50% of cases.4 This event is 
mainly attributed to abnormal adhesion of sickled red blood 
cells, granulocytes and platelets to the vascular endothelium, 
with production of proinflammatory mediators that stimulate 
the production of endothelial adhesion molecules.5 SCA is 
considered a chronic inflammatory disease characterized by 
an increased production of proinflammatory cytokines such 
as interleukin (IL)-6, IL-8 and tumor necrosis factor-alpha 
(TNF-a).6,7 
TNF-a is a cytokine with a large variety of properties 
that is involved in the activation of endothelial cells 
and leukocytes, the stimulation of macrophages and the 
recruitment and chemotaxis of inflammatory cells;8 it 
has been implicated in the pathogenesis of various acute 
and chronic states, including sepsis, chronic infections 
and inflammatory conditions. Additionally it plays an 
important role in the synthesis of acute phase proteins and 
in the expression of adhesion molecules by the vascular 
endothelium.9 In SCA, TNF-a has been linked as a risk factor 
for the occurrence of painful crises, as well as participating 
in the occlusion of the microcirculation.10 
Although the disease has a genetic cause common 
to all carriers, patients can manifest a variable clinical 
picture including severe alterations in the function 
of vital organs.5,9 Several factors may modulate the 
clinical features of SCA, such as fetal hemoglobin (Hb 
F), the β-globin haplotypes and co-association with 
thalassemia.11 The different haplotypes may influence Hb 
F levels and the clinical presentation of SCA patients. The 
Senegal haplotype, by producing the highest levels of fetal 
hemoglobin in the blood (> 15%), is associated with a less 
severe clinical evolution of SCA and a lower occurrence of 
organic damage. The clinical picture of the Benin haplotype 
is of intermediate severity, with Hb F levels between 5% and 
15%. The Bantu or CAR haplotype is associated with greater 
clinical severity and the lowest Hb F levels (< 5%).12,13 
Hydroxyurea (HU), used in the treatment of SCA, is a 
chemotherapeutic agent that increases the concentration of 
Hb F, thereby decreasing the polymerization of hemoglobin 
in deoxygenated states and reducing sickling.14 HU 
contributes to reduce the plasmatic expression of adhesion 
molecules as well as clinical episodes of acute chest 
syndrome and painful crises.15 Despite  the numerous 
benefits that the use of HU can bring to users, not all 
patients have sufficient clinical and laboratory criteria to 
be included in the treatment protocol.16 In addition, some 
patients refuse treatment because of the potential risks 
and side effects related to the use of HU.
In this context, the present study aimed to evaluate 
the profile of the proinflammatory cytokine TNF-a and its 
association with the haplotypes of the beta globin S and 
the use of HU.
Methods
A cross-sectional study was carried out with 67 volunteer 
patients of both genders, aged from 18-66 years with clinical 
and laboratory diagnosis of SCA, attended in the hematology 
service of a hospital in Fortaleza, Ceará, Brazil. Patients 
were at steady-state in accordance to criteria established by 
Ballas17 and were stratified in groups according to genotype 
and whether they received HU or not: Bantu/n [patients with 
Bantu/Bantu (n = 31) and Bantu/Atypical (n = 6) genotypes]; 
Bantu/Benin (n = 22) and Benin/Benin (n = 8). A group of 26 
healthy individuals was used as a control group.
The analysis of the haplotype cluster βS was performed 
by restriction fragment length polymorphism-polymerase 
chain reaction (PCR-RFLP). The level of the cytokine TNF-α 
was measured by the enzyme-linked immunosorbent assay 
(ELISA) test using cytokine kits (BD Biosciences ®). Laboratory 
data (complete blood count and Hb F concentration) and 
information regarding the use of HU were obtained from 
medical records.
The study was approved by the Research Ethics Committee 
of Hospital Universitário Walter Cantídio (HUWC) and was 
conducted in accordance with the Declaration of Helsinki as 
revised in 2008. Informed consent forms were signed by all 
participants.
Statistical analysis was performed with R software using 
the Kruskal-Wallis and Mann-Whitney tests. The results are 
expressed as means ± standard deviation (SD). The level of 
significance was set at 5% (p-value < 0.05).
Results
The clinical details of the steady-state SCA patients 
according to genotypes and the use of HU are shown in 
Tables 1 and 2, respectively. Of the 67 patients included in 
the study, 55.2% were female and 44.8% were male. The mean 
age was 35.48 (± 11.55) years. The patient group had a mean 
Hb concentration of 8.68 g/dL (± 1.36 g/dL), hematocrit (Ht) 
25.16% (± 3.9%) mean corpuscular volume (MCV) 100.05 fL 
(± 10.74  fL), mean corpuscular hemoglobin (MCH) 34.56 pg 
(± 4.27 pg), mean corpuscular hemoglobin concentration 
(MCHC) 34.33% (± 1.39%), leukocytes 1.26 × 109/L (± 1.58 × 
109/L), platelets 374.90 × 109/L (± 154.59 × 109/L), Hb F 12.17% 
(± 7.16%) and Hb S 81.32% (± 7.99%). The Bantu/n genotype 
was the most common; it was expressed in 37 of the patients 
(55.2%), followed by Bantu/Benin with 22 (32.8%) and Benin/
Benin with eight patients (11.9%). A total of 53 (79%) patients 
were treated with HU: 30 (44.8%) recieved a dose less than 20 
mg/kg/day and 23 (34.3%) recieved a larger dose; 31 (58.5%) 
received HU for a period of less than 20 months and 22 
(41.5%) for a longer period (Table 1).
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Total
 
Bantu/n
Bantu/
Benin
Benin/
Benin
 
p-value
Age (years) 35.5 ± 11.5 34.24 ± 
11.24
37.37 ± 
12.79
36.00 ±  
9.89
Gender - n (%)
   Male 30 (44.8) 16 (43.2) 11 (50) 3 (37.5)
   Female 37 (55.2) 21 (56.8) 11 (50) 5 (62.5)
Hb F (%) mean ± SD 12.17 ±  
7.16
12.32 ± 7.37 12.6 ±  
7.25
10.31 ±  
6.48
0.6395
Hb (g/dL) mean 
± SD
8.68 ±  
1.36
9.025 ± 1.12 7.97 ±  
1.44
9.06 ±  
1.56
0.0104a
Hematocrit (%) 
mean ± SD
25.16 ±  
3.90
26.02 ± 3.45 23.38 ± 
4.04
26.12 ±  
4.29
0.0297a
MCV (fL) mean ± SD 100.05 ± 
10.74
99.79 ± 9.68 100.4 ± 
12.65
100.5 ±  
11.18
0.9753
MCH (pg) mean 
± SD
34.56 ±  
4.27
34.38 ± 3.90 34.72 ± 
4.76
34.94 ±  
5.04
0.9262
MCHC (%) mean 
± SD
34.33 ±  
1.39
34,44 ± 1,38 34.04 ± 
1.33
34.64 ±  
1.64
0.4641
Leucocytes (x 109/L) 
mean ± SD
1.26 ±  
1.58
1.44 ±  
2.09
9.86 ±  
3.98
1.21 ±  
3.34
0.1590
Platelets (x 109/L) 
mean ± SD
3.75 ±  
1.55
4.05 ±  
1.41
3.24 ±  
1.90
3.69 ±  
6.65
0.0768
Hydroxyurea - n (%)
   Untreated 14 (21.0) 5 (13.5) 6 (27.3) 3 (37.5)
   Treated 53 (79.0) 32 (86.5) 16 (72.7) 5 (62.5)
Dose of HU - n (%)
   < 20 mg/kg/day 30 (44.8) 20 (54.1) 7 (31.8) 3 (37.5)
   ≥ 20 mg/kg/day 23 (34.3) 12 (32.4) 9 (40.9) 2 (25.0)
Time of treatment 
- n (%)
   < 20 months 31 (58.5) 18 (56.3) 10 (62.5) 13 (60.0)
   ≥ 20 months 22 (41.5) 14 (43.8) 6 (37.5) 2 (40.0)
MCV: mean corpuscular volume; MCH: mean corpuscular 
hemoglobin; MCHC: mean corpuscular hemoglobin concentration. 
a p-value < 0.05 
Statistical analysis using Kruskal-Wallis test
Table 1 - Clinical details of steady-state sickle cell 
anemia patients (n = 67) according to genotypes.
Serum levels of TNF-a were significantly higher in SCA patients 
compared to healthy individuals (p-value < 0.0001; Figure 1).
Regarding the use of HU, TNF-a levels were decreased in 
patients who were receiving treatment compared to those 
who were not (p-value = 0.1249; Figure 2). Patients who 
were receiving HU at a dose of < 20 mg/kg/day did not have 
significantly different TNF-a levels compared to those who 
received doses ≥ 20 mg/kg/day (p-value = 0.3045). Regarding the 
duration of treatment with HU, patients receiving the drug for a 
period greater than or equal to 20 months showed no statistical 
difference in the TNF-a levels when compared to patients who 
were treated with HU for less than 20 months (p-value = 0.3034).
When comparing TNF-a levels between βS-globin 
haplotypes, it was observed that the Bantu/n group had 
significantly higher TNF-a levels than the Bantu/Benin group 
(p-value = 0.0021; Figure 3).
  Treated with 
hydroxyurea
 
Untreated
 
p-value
Patients - n (%) 53 (79) 14 (21)
Age (years) mean ± SD 35.35 ± 11.62 35.92 ± 11.67
Gender - n (%)
   Male 23 (43.4) 7 (50)
   Female 30 (56.6) 7 (50)
Hb F (%) mean ± SD 13.28 ± 7.19 8.014 ± 5.470 0.0067a
Hb (g/dL) mean ± SD 8.93 ± 1.314 7.749 ± 1.168 0.0016a
Hematocrit (%) mean ± SD 25.85± 3.755 22.6 ± 3.458 0.0024a
MCV (fL) mean ± SD 100.9 ± 11.11 96.83 ± 8.846 0.1045
MCH (pg) mean ± SD 34.89 ± 4.334 33.30 ± 3.941 0.1082
MCHC (%) mean ± SD 34.35 ± 1.404 34.30 ± 1.419 0.4528
Leucocytes (× 109/L) mean 
± SD
1.26 ± 1.76 1.28 ± 0.47 0.0421a
Platelets (× 109/L) mean 
± SD
3.70 ± 1.55 3.92 ± 1.57 0.3858
MCV: mean corpuscular volume; MCH: mean corpuscular 
hemoglobin; MCHC: mean corpuscular hemoglobin concentration. 
a p-value < 0.05 
Statistical analysis using Kruskal-Wallis test.
Table 2 - Clinical details of steady-state sickle 
cell anemia patients (n = 67) according to use of 
hydroxyurea.
Figure 1 – Box plot comparing TNF-a levels between Control Group 
and sickle cell anemia patients Mann-Whitney test (p < 0.0001).
Discussion
The recurrent vaso-occlusion-ischemic processes induce a 
chronic inflammatory response in SCA patients, which is 
characterized by high levels of proinflammatory cytokines 
that activate the endothelium.18 The activated endothelium 
plays an important role in the initiation and propagation 
of the chronic inflammatory process that produces 
cytokines, including IL-8, IL-1 and IL-6. They contribute to 
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Regarding HU therapy, patients receiving treatment had 
lower TNF-a levels compared to patients who were not, but 
this difference was not significant. These results confirm 
those reported by Tavakkoli et al.19 who found no difference 
in the TNF-a serum levels in SCA patients at steady-state 
in relation to receiving HU or not. Furthermore, the authors 
found no difference between the vaso-occlusive crises of these 
patients. On the other hand, Lanaro at al.,20 in a study with 
50 SCA adult patients at steady-state on HU therapy, showed 
that they had significantly lower TNF-a levels compared to 26 
untreated patients. So, the effect of HU therapy on the release 
of inflammatory mediators is not well understood.
In the current study, a higher prevalence of the Bantu 
haplotype was found compared to the Benin haplotype. This 
result is in agreement with the study by Silva et al.12 who used 
the same population as ours and explained this result by the 
origins of the black population brought to the state of Ceará.
Studies of several different ethnic groups of SCA patients 
with distinct hematological characteristics suggested that the 
βS-globin gene cluster haplotype may be useful as a predictor of 
disease severity.22-25 Furthermore, Bakanay et al.26 demonstrated 
that the βS-globin gene cluster haplotype, independent of the 
Hb F level, is correlated to survival of SCA patients on HU 
therapy. In the present study, a significant increase of TNF-a 
levels was observed in the Bantu/n group compared to the 
Bantu/Benin group. This result can be explained by the fact 
that patients with the Bantu haplotype have a tendency of 
having more severe clinical manifestations because of the 
increased concentration of Hb S and decreased concentration 
of Hb F.27 Sickled red blood cells exhibit abnormal adhesion to 
the vascular endothelium, thus contributing to the expression 
of adhesion molecules and amplification of inflammation by 
proinflammatory cytokines such as TNF-alpha.8,28 
Conclusion
SCA expresses factors that influence the clinical features of 
the patients. In this study one of these factors was evidenced, 
showing the modulatory role of the β-globin haplotypes on 
TNF-a levels in SCA adults at steady-state. Many previous 
studies have investigated the prognosis and inflammatory 
state of SCA patients, but the discovery that  TNF-a levels vary 
according to the genetic polymorphism of the patient is a new 
finding.
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